Decompressive Craniectomy Following Trauma

Status Not yet recruiting

Clinical Trial Summary

A prospective clinical trial on trauma patients with increased intracranial pressure(ICP) applied for decompressive craniectomy to lower ICP

Clinical Trial Description

Traumatic brain injury (TBI) remains a major health problem across the globe . Intracranial pressure (ICP) following TBI can be elevated due to increasing mass effect from hematomas, contusions, and diffuse brain swelling. Decompressive craniectomy (DC) is a surgical procedure which involves removing a large part of the skull (bone flap) out to make more room for the swollen brain.Mass lesions can be acute subdural hematoma (ASDH), intraparenchymal, brain oedema, or a combination thereof. The most frequent indication for a DC is an acute subdural hematoma (ASDH). The first modern use of DC following TBI was done by Harvey Cushing in 1908. Cushing treated head-injured patients with a subtemporal DC and he reported a substantial reduction in mortality. The management of TBI progressed significantly in the 21st century due to advances in neuroimaging, prehospital management, neurointensive care, neuroanaesthesia, and rehabilitation. This led to a renaissance of interest in DC for improvement patient conditions. One of the serious concerns regarding DC is that it may reduce mortality, but increase the subset of patients with severe disability and persistent vegetative state. The discrepancy in published outcome may, to some extent, be explained by difference in patient selection, indications, timing , and technique of surgery. In terms of surgical consideration regarding DC, it is now well accepted that the dura mater has to be opened and the minimum diameter of unilateral DC should be around 11-12 cm. Skull reconstruction (cranioplasty) after improvement of neurological state is recommended. Decompressive craniectomy provides additional space for the swollen brain and can effectively reduce ICP, thereby mitigating the risk of herniation. However, despite the positive effect of DC on uncontrollable intracranial hypertension, the effect of surgical decompression in mortality and overall functional outcome following TBI remained controversial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04574349
Study type	Interventional
Source	Assiut University
Contact	Alaa M Oreaby
Phone	01008798181
Email	alaaoreaby@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	October 1, 2020
Completion date	October 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04562844` - Assessment and Rehabilitation of Social Cognition in People With Traumatic Brain Injury	N/A
Active, not recruiting	`NCT04313712` - Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure
Recruiting	`NCT04212754` - Management and Outcomes Following Emergency Surgery for Traumatic Brain Injury
Not yet recruiting	`NCT06370520` - Screening Emotions in Adolescents at the Hospital for mTBI
Completed	`NCT03822026` - Hyperventilation in Patients With Traumatic Brain Injury	N/A
Not yet recruiting	`NCT04946747` - Detection and Prevention of Concussive Injuries With Smart Technology.	N/A
Recruiting	`NCT03687528` - Platelet Inhibitor Treated Patients With Head Injury Trauma Meeting NICE Criteria : is the CT-scan Mandatory ?
Recruiting	`NCT04993495` - Study Evaluating the Potential Impact of a Hemorrhagic Risk Stratification Score in Patients With Mild Head Trauma
Not yet recruiting	`NCT03721003` - Intracranial Pressure Monitoring in Sever Traumatic Brain Injury Single Center Experience
Active, not recruiting	`NCT05490576` - Tau And Connectomics In TES Study	Phase 1
Completed	`NCT03870867` - The Emergency Department Falls Study
Completed	`NCT04225663` - A Meditation Intervention on Subconcussive Head Impacts	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.